# Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer

> **NCT07276789** · PHASE2 · RECRUITING · sponsor: **Integro Theranostics** · enrollment: 35 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** LS301-IT 0.1 mg/kg

## Key facts

- **NCT ID:** NCT07276789
- **Lead sponsor:** Integro Theranostics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2026-08
- **Final completion:** 2026-09
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07276789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07276789, "Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07276789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*